FindTrial
Sign In

Dabigatran Etexilate 150mg

DRUG5 trials

Sponsors

Boehringer Ingelheim, The Affiliated Hospital Of Guizhou Medical University, Kafrelsheikh University

Conditions

Atrial FibrillationCerebral Venous Sinus ThrombosisCombined Analysis of Polymorphisms and Dabigatran Pharmacokinetic ParametersPercutaneous Coronary Intervention

Phase 3

Evaluation of Dual Therapy With Dabigatran vs. Triple Therapy With Warfarin in Patients With AF That Undergo a PCI With Stenting (REDUAL-PCI)
CompletedNCT02164864
Boehringer IngelheimAtrial Fibrillation, Percutaneous Coronary Intervention
Start: 2014-07-22End: 2017-06-05Updated: 2018-07-31
Dabigatran Versus Apixaban in Cerebral Venous Thrombosis
RecruitingNCT06551415
Kafrelsheikh UniversityCerebral Venous Sinus Thrombosis
Start: 2021-08-01End: 2024-10-01Target: 200Updated: 2024-08-13
Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis
RecruitingNCT06551402
Kafrelsheikh UniversityCerebral Venous Sinus Thrombosis
Start: 2024-08-09End: 2026-11-01Target: 200Updated: 2024-08-13

Phase 4

Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation (RE-CIRCUIT)
CompletedNCT02348723
Boehringer IngelheimAtrial Fibrillation
Start: 2015-04-28End: 2016-11-14Updated: 2018-01-29

Unknown Phase

Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran
Not yet recruitingNCT06387407
The Affiliated Hospital Of Guizhou Medical UniversityCombined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters
Start: 2024-05-01End: 2025-11-25Target: 30Updated: 2024-04-29

Related Papers

Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: Integrated analysis of 2 randomized controlled clinical trials.
2021-01-255 citations
Dabigatran Dual Therapy vs Warfarin Triple Therapy Post-Percutaneous Coronary Intervention in Patients with Atrial Fibrillation With/Without a Proton Pump Inhibitor: A Pre-Specified Analysis of the RE-DUAL PCI Trial
Drugs2020-06-1917 citations
Comparison of Dabigatran Plus a P2Y<sub>12</sub> Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.
2020-05-075 citations
Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention
Circulation Cardiovascular Interventions2020-04-0124 citations
P34 The effect of sex on the efficacy and safety of dabigatran dual therapy in atrial fibrillation after PCI: a subgroup analysis from the RE-DUAL PCI trial
European Heart Journal2020-01-01
Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI.
2019-08-019 citations
Regional differences in patient characteristics and outcomes during uninterrupted anticoagulation with dabigatran versus warfarin in catheter ablation of atrial fibrillation: the RE-CIRCUIT study
Journal of Interventional Cardiac Electrophysiology2019-02-133 citations
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
New England Journal of Medicine2017-08-271323 citations
Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation
New England Journal of Medicine2017-03-19431 citations